DrugPatentWatch Database Preview➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing
« Back to Dashboard
GDC-0853 is an investigational drug.
There have been 175 clinical trials for GDC-0853. The most recent clinical trial was a Phase 3 trial, which was initiated on July 1st 2010.
The most common disease conditions in clinical trials are Breast Neoplasms, Carcinoma, and Lymphoma. The leading clinical trial sponsors are Genentech, Inc., National Cancer Institute (NCI), and Hoffmann-La Roche.
Recent Clinical Trials for GDC-0853
|Testing the Addition of Abemaciclib to Olaparib for Women With Recurrent Ovarian Cancer||National Cancer Institute (NCI)||Phase 1|
|A Study Evaluating the Efficacy and Safety of GDC-9545 Compared With Physician's Choice of Endocrine Monotherapy in Participants With Previously Treated Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer||Hoffmann-La Roche||Phase 2|
|To Evaluate the Safety and Efficacy of Ipatasertib (GDC-0068) in Combination With Paclitaxel in Platinum-resistant Recurrent Epithelial Ovarian Cancer||Icahn School of Medicine at Mount Sinai||Phase 2|